Dydrogest Special Precautions

Before starting treatment with Dydrogesterone because of dysfunctional uterine bleeding an organic cause should be excluded.
Breakthrough bleeding and spotting may occur during the first months of treatment. If breakthrough bleeding and spotting continue to occur when treatment has already been underway for some time, or continue when treatment is discontinued, the cause of this should be ascertained, if necessary by taking an endometrial biopsy to exclude malignancy of the endometrium.
If one of the following disorders occurs during use for the first time or gets worse, stopping the treatment should be considered: Exceptionally severe headache, migraine or symptoms that may indicate cerebral ischemia.
Marked increase in blood pressure.
Occurrence of venous thromboembolism.
Conditions for which monitoring are necessary: It is known that the following rarely occurring conditions may be affected by sex hormones and may arise or get worse during pregnancy or during the use of sex hormones: cholestatic icterus, herpes gestationis, severe pruritus, otosclerosis and porphyria.
Patients with a history of depression must be carefully monitored; if severe depression recurs, treatment with Dydrogesterone must be stopped.
Other conditions: Patients with rare hereditary conditions such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not use this medicinal product.